Literature DB >> 15927843

New cytotoxic agents: a review of the literature.

Katsuyuki Hotta1, Hiroshi Ueoka.   

Abstract

The goal of treatment for patients with advanced cancer is to prolong survival, control symptoms, and reduce disease-related complications. Despite the introduction of many cytotoxic agents during the past decade, only modest improvement in survival has been achieved. In order to urgently improve these situations, new cytotoxic agents as well as molecular-targeted agents are now under investigation. In this article, we reviewed the latest information regarding antitumor activity, toxicity, pharmacokinetics, and clinical application of the new cytotoxic agents.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15927843     DOI: 10.1016/j.critrevonc.2005.01.006

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN: 1040-8428            Impact factor:   6.312


  4 in total

1.  Cytotoxic activity of new acetoxycoumarin derivatives in cancer cell lines.

Authors:  Musiliyu A Musa; Veera L D Badisa; Lekan M Latinwo; John Cooperwood; Andre Sinclair; Ahkinyala Abdullah
Journal:  Anticancer Res       Date:  2011-06       Impact factor: 2.480

2.  Therapeutic anticancer efficacy of a synthetic diazonamide analog in the absence of overt toxicity.

Authors:  Noelle S Williams; Anthony W G Burgett; Ashley S Atkins; Xiaodong Wang; Patrick G Harran; Steven L McKnight
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-07       Impact factor: 11.205

Review 3.  Role of survival post-progression in phase III trials of systemic chemotherapy in advanced non-small-cell lung cancer: a systematic review.

Authors:  Katsuyuki Hotta; Katsuyuki Kiura; Yoshiro Fujiwara; Nagio Takigawa; Akiko Hisamoto; Eiki Ichihara; Masahiro Tabata; Mitsune Tanimoto
Journal:  PLoS One       Date:  2011-11-17       Impact factor: 3.240

4.  The critical role of novel benzophenone analogs on tumor growth inhibition targeting angiogenesis and apoptosis.

Authors:  Yasser Hussein Eissa Mohammed; Shaukath Ara Khanum
Journal:  Medchemcomm       Date:  2018-02-15       Impact factor: 3.597

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.